CL2016001345A1 - Producto farmacéutico que comprende a un inhibidor de la interacción mdm2-p53 y b citarabina y uso para el tratamiento del cáncer. - Google Patents

Producto farmacéutico que comprende a un inhibidor de la interacción mdm2-p53 y b citarabina y uso para el tratamiento del cáncer.

Info

Publication number
CL2016001345A1
CL2016001345A1 CL2016001345A CL2016001345A CL2016001345A1 CL 2016001345 A1 CL2016001345 A1 CL 2016001345A1 CL 2016001345 A CL2016001345 A CL 2016001345A CL 2016001345 A CL2016001345 A CL 2016001345A CL 2016001345 A1 CL2016001345 A1 CL 2016001345A1
Authority
CL
Chile
Prior art keywords
mdm2
cancer
treatment
pharmaceutical product
cytarabine
Prior art date
Application number
CL2016001345A
Other languages
English (en)
Inventor
Kathryn E Packman
Brian Higgins
Gwen Nichols
Original Assignee
F Hoffmann Laroche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52014047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016001345(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann Laroche Ag filed Critical F Hoffmann Laroche Ag
Publication of CL2016001345A1 publication Critical patent/CL2016001345A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

PRODUCTO FARMACÉUTICO QUE COMPRENDE A UN INHIBIDOR DE LA INTERACCIÓN MDM2-P53 Y CITARABINA COMO PREPARACIÓN COMBINADA PARA LA UTILIZACIÓN EN EL TRATAMIENTO DEL CÁNCER, TAL COMO LEUCEMIA MIELOIDE AGUDA.
CL2016001345A 2013-12-05 2016-06-02 Producto farmacéutico que comprende a un inhibidor de la interacción mdm2-p53 y b citarabina y uso para el tratamiento del cáncer. CL2016001345A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361912152P 2013-12-05 2013-12-05

Publications (1)

Publication Number Publication Date
CL2016001345A1 true CL2016001345A1 (es) 2017-04-07

Family

ID=52014047

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001345A CL2016001345A1 (es) 2013-12-05 2016-06-02 Producto farmacéutico que comprende a un inhibidor de la interacción mdm2-p53 y b citarabina y uso para el tratamiento del cáncer.

Country Status (31)

Country Link
US (5) US20160303158A1 (es)
EP (1) EP3077004B1 (es)
JP (3) JP6297695B2 (es)
KR (1) KR101862955B1 (es)
CN (1) CN105792847B (es)
AR (1) AR098576A1 (es)
AU (1) AU2014359422B2 (es)
BR (1) BR112016009669B1 (es)
CA (1) CA2926307C (es)
CL (1) CL2016001345A1 (es)
CR (1) CR20160173A (es)
DK (1) DK3077004T3 (es)
EA (1) EA201690785A1 (es)
ES (1) ES2785203T3 (es)
HK (1) HK1222808A1 (es)
HR (1) HRP20200566T1 (es)
HU (1) HUE049434T2 (es)
IL (1) IL244888B (es)
LT (1) LT3077004T (es)
MA (1) MA39040A1 (es)
MX (1) MX370618B (es)
PE (1) PE20160591A1 (es)
PH (1) PH12016500933A1 (es)
PL (1) PL3077004T3 (es)
PT (1) PT3077004T (es)
RS (1) RS60142B1 (es)
SG (1) SG11201604504VA (es)
SI (1) SI3077004T1 (es)
TW (2) TWI627954B (es)
WO (1) WO2015082384A1 (es)
ZA (1) ZA201602829B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101730708B (zh) 2007-03-28 2013-09-18 哈佛大学校长及研究员协会 缝合多肽
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
WO2013059525A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
EP2914256B1 (en) 2012-11-01 2019-07-31 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
SG11201604504VA (en) * 2013-12-05 2016-07-28 Hoffmann La Roche Novel combination treatment for acute myeloid leukemia (aml)
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
BR112017005736A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e formulações dos mesmos
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
KR20180043835A (ko) * 2015-09-03 2018-04-30 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 매크로사이클 및 이의 용도
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
JP7163281B2 (ja) * 2016-06-06 2022-10-31 セルジーン コーポレイション ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドによる血液系悪性腫瘍の治療
WO2018027477A1 (zh) * 2016-08-08 2018-02-15 肖飞 螺环吲哚酮聚乙二醇碳酸酯类化合物和其组合物、制备方法及用途
JP6890659B2 (ja) 2016-11-15 2021-06-18 ノバルティス アーゲー ＨＤＭ２−ｐ５３相互作用阻害剤の用量およびレジメン
US20200281925A1 (en) * 2017-03-31 2020-09-10 Novartis Ag Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
JP7126556B2 (ja) 2018-09-28 2022-08-26 富士フイルム株式会社 シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤
TW202118488A (zh) * 2019-07-26 2021-05-16 大陸商蘇州亞盛藥業有限公司 Mdm2抑制劑的藥物組合物及其在預防和/或治療疾病中的用途
EP4337228A1 (en) * 2021-05-13 2024-03-20 Nkarta, Inc. Dosing regimens for cancer immunotherapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125888B2 (en) * 2002-05-02 2006-10-24 Merck & Co., Inc. Tyrosine kinase inhibitors
DE102005012681A1 (de) * 2005-03-18 2006-09-21 Weber, Lutz, Dr. Neue 1,5-Dihydro-pyrrol-2-one
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CN101773408B (zh) * 2010-01-15 2012-04-04 平荧 多功能排针结合电凝固技术提升下垂皮肤的装置
JP2013523820A (ja) * 2010-04-09 2013-06-17 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン 疾患を処置する際に使用するためのｍｄｍ２阻害剤のバイオマーカー
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US20120010235A1 (en) * 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
US8993614B2 (en) * 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
SG11201604504VA (en) * 2013-12-05 2016-07-28 Hoffmann La Roche Novel combination treatment for acute myeloid leukemia (aml)
US9657351B2 (en) * 2013-12-06 2017-05-23 Hoffman-La Roche Inc. MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist

Also Published As

Publication number Publication date
SI3077004T1 (sl) 2020-07-31
HRP20200566T1 (hr) 2020-06-26
US20200253999A1 (en) 2020-08-13
CN105792847B (zh) 2019-11-08
US9956243B2 (en) 2018-05-01
PE20160591A1 (es) 2016-06-11
HUE049434T2 (hu) 2020-09-28
LT3077004T (lt) 2020-05-11
MX2016007170A (es) 2016-09-08
PT3077004T (pt) 2020-04-16
US20150157603A1 (en) 2015-06-11
PL3077004T3 (pl) 2020-08-10
TWI678204B (zh) 2019-12-01
TWI627954B (zh) 2018-07-01
RS60142B1 (sr) 2020-05-29
AU2014359422A1 (en) 2016-04-28
JP2016539160A (ja) 2016-12-15
SG11201604504VA (en) 2016-07-28
US20220031726A1 (en) 2022-02-03
DK3077004T3 (da) 2020-04-27
TW201526890A (zh) 2015-07-16
ZA201602829B (en) 2017-04-26
CA2926307C (en) 2021-11-16
US20230381215A1 (en) 2023-11-30
WO2015082384A1 (en) 2015-06-11
IL244888A0 (en) 2016-05-31
TW201840310A (zh) 2018-11-16
MA39040A1 (fr) 2018-01-31
JP2018111700A (ja) 2018-07-19
ES2785203T3 (es) 2020-10-06
EP3077004A1 (en) 2016-10-12
US20160303158A1 (en) 2016-10-20
KR101862955B1 (ko) 2018-05-31
HK1222808A1 (zh) 2017-07-14
IL244888B (en) 2020-11-30
JP2021091690A (ja) 2021-06-17
AU2014359422B2 (en) 2020-03-05
BR112016009669A8 (pt) 2020-04-07
JP6297695B2 (ja) 2018-03-20
CN105792847A (zh) 2016-07-20
PH12016500933A1 (en) 2016-06-27
EP3077004B1 (en) 2020-02-19
AR098576A1 (es) 2016-06-01
EA201690785A1 (ru) 2016-10-31
JP6918724B2 (ja) 2021-08-11
CA2926307A1 (en) 2015-06-11
CR20160173A (es) 2016-06-08
MX370618B (es) 2019-12-17
KR20160070190A (ko) 2016-06-17
BR112016009669B1 (pt) 2023-01-24

Similar Documents

Publication Publication Date Title
CL2016001345A1 (es) Producto farmacéutico que comprende a un inhibidor de la interacción mdm2-p53 y b citarabina y uso para el tratamiento del cáncer.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
CL2019000542A1 (es) Compuestos de tetraciclina y métodos de uso de los mismos.
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2015002151A1 (es) Biaril amide compuestos como inhibidores de quinasa
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
MX356368B (es) Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
CL2015003491A1 (es) Compuestos químicos.
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
CL2015000711A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch; composicion farmaceutica y uso en el tratamiento del cancer.
CL2016003260A1 (es) Profármacos de gemcitabina
UY36075A (es) Derivados de tubulisina
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
UY34761A (es) Composiciones parasiticidas que comprenden derivados de benzimidazol, métodos y usos de los mismos.